Showing 431-440 of 1861 results for "".
An Update on At-Home UVB Phototherapy
https://practicaldermatology.com/topics/general-topics/an-update-on-at-home-uvb-phototherapy/21786/At-home options increase accessibility to phototherapy, which is effective and generally safe for psoriasis management.Now It’s Personal: A Closer Look at PRP for Hair Loss Treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/now-its-personal-a-closer-look-at-prp-for-hair-loss-treatment/23936/High-cost but low-risk platelet-rich plasma injections can be an elegant option for short-term hair loss treatment.Dupixent for Adolescents priority review, Restylane Lyft via cannulas, Hyperhidrosis Awareness
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-dupixent-for-adolescents-priority-review-restylane-lyft-via-cannulas-hyperhidrosis-awareness/18215/FDA grants priority review for Sanofi's and Regeneron's sBLA for Dupixent (dupilumab) for adolescents. Galderma's Restylane Lyft is approved for use with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. TA Biologic Test for Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/a-biologic-test-for-cutaneous-squamous-cell-carcinoma/24025/Cutaneous squamous cell carcinoma (cSCC) encompasses a broad spectrum of disease severity, from superficial and easily treatable skin lesions to potentially life-threatening metastatic cancer. Adjuvant radiation therapy (ART) is recommended to reduce the likelihood of relapse following surgical reseDermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveTreating Psoriasis with FDA-Approved Medications in 2020
https://practicaldermatology.com/topics/psoriasis/treating-psoriasis-with-fda-approved-medications-in-2020/23212/A reference for all of the FDA-approved medications separated into topical treatments and systemic treatments.FDA Approvals, Acne Insights, EPI Gets Cloderm
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approvals-acne-insights-epi-gets-cloderm/18230/In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US maySummer AAD NYC Updates; Modernizing Medicine Grows
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-summer-aad-nyc-updates-modernizing-medicine-grows-/18444/As in years past, the summer meeting of the AAD has focused attention on optimal uses for both existing and emerging therapies in the dermatology clinic, including, PRP. Dr. Nicole Rogers assessed the role of PRP for hair loss. Diane Berson, MD discusses acne, Adam Friedman, MD addresses the microbiL'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-l-oreal-nabs-cerave-smart-beauty-tools-skin-cancer-knowledge-lacking/18703/Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell itsLong-Term Effects of Neuromodulators on Aging
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/long-term-effects-of-neuromodulators-on-aging/18810/Shannon Humphrey, MD discusses the cumulative anti-aging benefits of long-term treatments with botulinum toxin type A. She shares her observations from the bench and offers a review of what the literature shows to support her recommendation for regular conservative neuromodulator treatments to impro